Matches in Wikidata for { <http://www.wikidata.org/entity/Q66031807> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q66031807 description "clinical trial" @default.
- Q66031807 description "ensayu clínicu" @default.
- Q66031807 description "klinisch onderzoek" @default.
- Q66031807 description "клінічне випробування" @default.
- Q66031807 name "Fosamprenavir Versus Other Protease Inhibitors" @default.
- Q66031807 name "Fosamprenavir Versus Other Protease Inhibitors" @default.
- Q66031807 type Item @default.
- Q66031807 label "Fosamprenavir Versus Other Protease Inhibitors" @default.
- Q66031807 label "Fosamprenavir Versus Other Protease Inhibitors" @default.
- Q66031807 prefLabel "Fosamprenavir Versus Other Protease Inhibitors" @default.
- Q66031807 prefLabel "Fosamprenavir Versus Other Protease Inhibitors" @default.
- Q66031807 P1132 Q66031807-6D074D80-80E0-45D9-9302-F6EE3B4B172A @default.
- Q66031807 P131 Q66031807-F4146B62-F2CF-4A83-ADA7-3C2F3DFF7DC9 @default.
- Q66031807 P1476 Q66031807-F19D0F1A-3816-4296-8E4B-FA3FC079ED00 @default.
- Q66031807 P17 Q66031807-3CF21FBC-E0CE-40CE-A088-2841A2C2B145 @default.
- Q66031807 P2899 Q66031807-CCBFB766-F50F-437A-A055-2756121424D0 @default.
- Q66031807 P3098 Q66031807-50543673-84CB-4E5E-84E3-44D3BBB38497 @default.
- Q66031807 P31 Q66031807-745CE145-CD3F-48B9-B49B-EA84951FC4FC @default.
- Q66031807 P4844 Q66031807-BF5CA3AE-6468-4DDD-906E-D041BEF7E71C @default.
- Q66031807 P580 Q66031807-4EC74F38-DE0E-48FB-9B2A-52DE4CDC1BDD @default.
- Q66031807 P582 Q66031807-A684FA0A-BD99-43F7-AEF4-8944E7DB45FB @default.
- Q66031807 P6099 Q66031807-7AF1F14C-E74B-40DD-8D07-E126B6F95FDA @default.
- Q66031807 P6153 Q66031807-53369DDB-9ED9-401B-9111-8335352E25D0 @default.
- Q66031807 P767 Q66031807-ADDF5BB7-8DF6-4BB4-9931-39AA9C733645 @default.
- Q66031807 P8363 Q66031807-3C927CCF-AAB6-40BC-8158-34143F3F9272 @default.
- Q66031807 P1132 "+314" @default.
- Q66031807 P131 Q1183 @default.
- Q66031807 P1476 "A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks" @default.
- Q66031807 P17 Q30 @default.
- Q66031807 P2899 "+18" @default.
- Q66031807 P3098 "NCT00094523" @default.
- Q66031807 P31 Q30612 @default.
- Q66031807 P4844 Q50315992 @default.
- Q66031807 P580 "2004-12-14T00:00:00Z" @default.
- Q66031807 P582 "2007-06-29T00:00:00Z" @default.
- Q66031807 P6099 Q42824827 @default.
- Q66031807 P6153 Q212322 @default.
- Q66031807 P767 Q212322 @default.
- Q66031807 P8363 Q78089383 @default.